LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Aperta

39.58 0.92

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

39.01

Massimo

39.99

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
EPS	-0.5
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+33.18% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	408M 6B
Apertura precedente	38.66
Chiusura precedente	39.58

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 feb 2026, 23:25 UTC

Azioni calde

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Utili

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Discorsi di Mercato

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Utili

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Utili

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Utili

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Utili

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Utili

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Utili

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Utili

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Discorsi di Mercato

Utili

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Discorsi di Mercato

Utili

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Discorsi di Mercato

Utili

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Utili

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Utili

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Utili

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Utili

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

33.18% in crescita

Previsioni per 12 mesi

Media 52.18 USD 33.18%

Alto 67 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.